|
Pegaptanib
Pegaptanib
|
| (IUPAC) ime
|
| RNK, ((2'-deoksi-2'-fluoro)C-Gm-Gm-A-A-(2'-deoksi-2'-fluoro)U-(2'-deoksi-2'-fluoro)C-Am-Gm-(2'-deoksi-2'-fluoro)U-Gm-Am-Am-(2'-deoksi-2'-fluoro)U-Gm-(2'-deoksi-2'-fluoro)C-(2'-deoksi-2'-fluoro)U-(2'-deoksi-2'fluoro)U-Am-(2'-deoksi-2'-fluoro)U-Am-(2'-deoksi-2'-fluoro)C-Am-(2'-deoksi-2'-fluoro)U-(2'deoksi-2'-fluoro)C-(2'-deoksi-2'-fluoro)C-Gm-(3'→3')-dT), 5'-estar sa α,α'-[4,12-diokso-6[[[5-(fosfoonoksi)pentil]amino]karbonil]-3,13-dioksa-5,11-diaza-1,15-pentadekanediil]bis[ω-metoksipoli(oksi-1,2-etanediil)], natrijum so[1]
|
| Klinički podaci
|
| AHFS/Drugs.com
|
Monografija
|
| Identifikatori
|
| CAS broj
|
222716-86-1
|
| ATC kod
|
S01LA03
|
| PubChem[2][3]
|
24847876
|
| DrugBank
|
DB04895
|
| ChEMBL[4]
|
CHEMBL1201704  Y
|
| Hemijski podaci
|
| Formula
|
C294H342F13N107Na28O188P28[C2H4O]2n (n≈900)
|
| Mol. masa
|
~50 Da
|
| SMILES
|
eMolekuli & PubHem
|
| InChI |
|---|
InChI=1S/C20H40N3O10P.Na.H/c1-29-13-15-31-19(25)22-11-7-5-9-17(23-20(26)32-16-14-30-2)18(24)21-10-6-4-8-12-33-34(3,27)28;;/h17H,4-16H2,1-3H3,(H,21,24)(H,22,25)(H,23,26)(H,27,28);;
Key: NMHKBPDWHKBFTD-UHFFFAOYSA-N Y |
|
| Farmakokinetički podaci
|
| Poluvreme eliminacije
|
10 dana
|
| Farmakoinformacioni podaci
|
| Trudnoća
|
?
|
| Pravni status
|
|
| Način primene
|
Intravitrealno
|
Pegaptanib natrijum injekcija (prodajno ime Macugen) je inhibitor angiogeneze, koji se koristi za lečenje neovaskularne (vlažne) starosne makularne degeneracije (AMD).[5][6][7][8][9][10]
Reference
- ↑ Drug Information: Pegaptanib Sodium Injection Arhivirano 2013-12-14 na Wayback Machine-u
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
- ↑ „Macugen (pegaptanib)”. European Medicines Agency: 1–3. 2010. Arhivirano iz originala na datum 2013-12-13. Pristupljeno 2013-12-08.
- ↑ Vinores SA: Pegaptanib in the treatment of wet, age-related macular degeneration. Int J Nanomedicine. 2006;1(3):263-8. PMID 17717967
- ↑ Wylegala E, Teper SJ: [VEGF in age-related macular degeneration. Part II. VEGF inhibitors use in age-related macular degeneration treatment] Klin Oczna. 2007;109(1-3):97-100. PMID 17687925
- ↑ Bakri SJ, Pulido JS, McCannel CA, Hodge DO, Diehl N, Hillemeier J: Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye. 2007 Aug 10;. PMID 17693999
- ↑ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. DOI:10.1093/nar/gkq1126. PMC 3013709. PMID 21059682. edit
- ↑ David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. DOI:10.1093/nar/gkm958. PMC 2238889. PMID 18048412. edit
Literatura
Spoljašnje veze
|
|
